DAFNA Capital Management’s F-star Therapeutics, Inc. Common Stock FSTX Stock Holding History

DAFNA Capital Management’s Portfolio FSTX Stock Details FSTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-576,881	Closed	-$3.65M	–	81
2022 Q4	$3.65M	Hold	576,881	–	–	1.03%	30
2022 Q3	$2.95M	Hold	576,881	–	–	0.79%	34
2022 Q2	$3.61M	Sell	576,881 -116,904	-17%	-$394K	0.98%	33
2022 Q1	$2.46M	Hold	693,785	–	–	0.64%	44
2021 Q4	$3.48M	Hold	693,785	–	–	0.88%	31
2021 Q3	$5.08M	Sell	693,785 -20,500	-3%	-$141K	1.35%	20
2021 Q2	$6.14M	Buy	+714,285	New	+$6.09M	1.28%	22
2017 Q4	–	Sell	-1,627	Closed	-$110K	–	79
2017 Q3	$110K	Buy	1,627 +1,227	+307%	+$70.3K	0.07%	70
2017 Q2	$217K	Buy	+400	New	+$18.5K	0.15%	66
2017 Q1	–	Sell	-6,853	Closed	-$219K	–	78
2016 Q4	$219K	Buy	+6,853	New	+$251K	0.19%	61

DAFNA Capital Management's FSTX Position: Q1 2023 in Review

DAFNA Capital Management sold out of F-star Therapeutics, Inc. Common Stock (FSTX) in Q1 2023, closing a stake of 576,881 shares — an estimated $3.65M sold.

DAFNA Capital Management first reported a position in FSTX in Q4 2016 and held it in 10 quarters. The position peaked at $6.14M in Q2 2021. 0 funds tracked by Wall St. Rank hold FSTX as of Q1 2023.

DAFNA Capital Management reported no remaining F-star Therapeutics, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
DAFNA Capital Management sold 576,881 F-star Therapeutics, Inc. Common Stock shares in Q1 2023, an estimated $3.65M.
DAFNA Capital Management first reported a position in F-star Therapeutics, Inc. Common Stock in Q4 2016 and held it in 10 quarters.
DAFNA Capital Management's F-star Therapeutics, Inc. Common Stock position peaked at $6.14M in Q2 2021.
0 funds tracked by Wall St. Rank held F-star Therapeutics, Inc. Common Stock as of Q1 2023.

Based on DAFNA Capital Management's 13F filing for Q1 2023, filed 15 May 2023.